Launch week offerEnds in00h00m00s

annual Promonthly Pro

Hiroki Ishihara

Assistant professor

Tokyo Women's Medical University

Japan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

About

Hiroki Ishihara serves as an Assistant Professor at Tokyo Women's Medical University in Japan. His research primarily focuses on advanced renal cell carcinoma, particularly examining the outcomes of various combination therapies and the impact of patient characteristics on treatment efficacy. Recent publications include studies on immune checkpoint inhibitors and tyrosine kinase inhibitors, as well as translational research bridging basic and clinical insights in this area.

Articles (28)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

YUKI KOBARI

Assistant Professor

Tokyo Women's Medical University

JAPAN

View details

Yu-Yu Liu

Project Assistant Professor

Hoshi University

JAPAN

View details

Toshio Takagi

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hiroki Ishihara

Research Interests

Make your next move.

Explore related searches

About

Articles (28)

Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Factors Associated With Trifecta and Pentafecta Achievement in Robot‐Assisted Laparoscopic Partial Nephrectomy for Highly Complex Renal Tumors

Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors

Treatment Profile of First‐Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End‐Stage Renal Disease on Dialysis

Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumab

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma

Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations

Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma

Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma

High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinoma

Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma

Translational Research Bridging Basic and Clinical Insights in Renal Cell Carcinoma: A Collaborative Review and Future Directions

Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma

Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma

Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era

Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma

Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Editorial Comment to Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study

Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma

Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study

Editorial Comment on Disease‐free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results‐Medicare data

Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma

Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors

Editorial Comment from Dr Ishihara et al. to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese high‐volume center

Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up

Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria

Collaborators (3)

YUKI KOBARI

Yu-Yu Liu

Toshio Takagi

Make your next move.